Last reviewed · How we verify
A: pacritinib
JAK2 inhibitor
JAK2 inhibitor Used for Myelofibrosis.
At a glance
| Generic name | A: pacritinib |
|---|---|
| Also known as | A: pacritinib 400mg |
| Sponsor | CTI BioPharma |
| Drug class | JAK inhibitor |
| Target | JAK2 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 1 |
Mechanism of action
Pacritinib is a potent and selective inhibitor of the JAK2 enzyme, which plays a key role in the signaling pathways that regulate cell growth and survival.
Approved indications
- Myelofibrosis
Common side effects
- Anemia
- Thrombocytopenia
- Neutropenia